Latest News

Here you find the latest news revolving Sensidose.

Press release

Sollentuna September 15, 2016 PRESS RELEASE The pharmaceutical company Sensidose AB announces that the company has passed important milestones: • Flexilev® for the treatment of Parkinson's disease is subsidized in Sweden • Approved national marketing authorisation...

Press release

Sollentuna September 15, 2016 PRESS RELEASE The pharmaceutical company Sensidose AB announces that the company has passed important milestones: • Flexilev® for the treatment of Parkinson's disease is subsidized in Sweden • Approved national marketing authorisation...

Flexilev included in the pharmaceutical benefits program

Flexilev included in the pharmaceutical benefits program from 2016-05-21!
 The Dental and Pharmaceutical Benefits Agency (TLV) decided on 20 May 2016 to include Flexilev in the subsidized medicines with the following conditions and restrictions: "Limitation of the...

Flexilev included in the pharmaceutical benefits program

Flexilev included in the pharmaceutical benefits program from 2016-05-21!
 The Dental and Pharmaceutical Benefits Agency (TLV) decided on 20 May 2016 to include Flexilev in the subsidized medicines with the following conditions and restrictions: "Limitation of the...

Sensidose participates in a Vinnova project

Sensidose participates in a Vinnova project regarding evaluation of symptoms and improved treatment of Parkinson's disease. Vinnova has distributed 60 million SEK to projects within the area "Innovations for Future Health". Within the framework of this program,...

International Congress of Parkinson’s Disease

Sensidose was one of 28 exhibitors during the 18th International Congress of Parkinson's Disease and Movement Disorders which took place between 8th to 12th of June 2014 in Stockholm. This was an excellent opportunity to present to an international audience the...